Skip to main content

Clinical findings and genetic analysis of patients with copy number variants involving 17p13.3 using a single nucleotide polymorphism array: a single-center experience



17p13.3 microdeletions or microduplications (collectively known as copy number variants or CNVs) have been described in individuals with neurodevelopmental disorders. However, 17p13.3 CNVs were rarely reported in fetuses. This study aims to investigate the clinical significance of 17p13.3 CNVs with varied sizes and gene content in prenatal and postnatal samples.


Eight cases with 17p13.3 CNVs out of 8806 samples that had been subjected to single nucleotide polymorphism array analysis were retrospectively analyzed, along with karyotyping, clinical features, and follow-up.


Eight cases with 17p13.3 CNVs consisted of five fetuses, one aborted embryo and two probands manifested severe congenital defects. The indications of prenatal testing varied considerably for the five fetuses, including ultrasound abnormalities (n = 3), segmental deletions indicated by non-invasive prenatal testing (n = 1), and intellectual disability in the mother of one fetus (n = 1). Of them, two and six harbored copy number gains and losses involving 17p13.3, respectively. The size of the detected 17p13.3 CNVs ranged from 576 kb to 5.7 Mb. Case 1 was diagnosed with 17p13.3 duplication syndrome, and cases 4, 6, and 7 with Miller–Dieker syndrome (MDS). Microdeletions of the 17p13.3 region in two cases (cases 5 and 8) involving YWHAE and CRK, sparing PAFAH1B1, were classified as pathogenic. Case 2 harbored a 576 kb microduplication, encompassing YWHAE and CRK but not PAFAH1B1, which was of maternal origin and considered a variant of uncertain significance. Case 3 carried one 74.2 Mb mosaic duplication of approximately 3.5 on chromosome 17p13.2q25.3, and two deletions at 17p13.3p13.2 and 17q25.3. The karyotype of case 3 was 46,XY,r(17)(p13q25). For five fetuses, only case 2 continued gestation and showed normal development at the age of 15 months; the others were subjected to termination of pregnancy.


The clinical findings of 17p13.3 microdeletions or microduplications varied among subjects, and 17p13.3 CNVs often differ in size and gene content. Microdeletions or microduplications containing the typical MDS region, as well as the microdeletions involving YWHAE and CRK, could be classified as pathogenic. The clinical significance of small duplications including YWHAE and CRK but not PAFAH1B1 remains uncertain, for which parental testing and clinical heterogeneity should be considered in genetic counseling.

Peer Review reports


Miller–Dieker syndrome (MDS) is a rare autosomal genetic disorder caused by a ~ 1.3 Mb deletion of the 17p13.3 chromosome region, which contains PAFAH1B1 (previously known as LIS1) and YWHAE, also known as 17p13.3 deletion syndrome, which affects approximately one in 13,000–20,000 newborns. Patients with this syndrome typically present with severe lissencephaly, dysmorphic facial features, and severe neurological abnormalities [1, 2]. Haploinsufficiency of PAFAH1B1 (encoding LIS1) causes an isolated lissencephaly sequence. Deletions extending distally, including the gene YWHAE (encoding 14-3-3-epsilon), are associated with a more severe grade of lissencephaly and additional features observed in MDS [3]. Reciprocally, individuals with duplication of MDS region display variable clinical phenotypes, including structural brain abnormalities (involving the corpus callosum, cerebellar vermis, and cranial base), hypotonia, intellectual disability, a relatively distinct facial phenotype, and other variable findings [2]. Both conditions show distinct but overlapping phenotypes and often have poor prognosis, underscoring the importance of prenatal diagnosis of these disorders.

With the advent of fetal ultrasound and magnetic resonance imaging (MRI), cranial and extracranial abnormalities associated with MDS can now be prenatally identified. These abnormalities include widespread agyria, abnormal Sylvian fissure and insula, ventriculomegaly, corpus callosum dysgenesis/agenesis, microcephaly, intrauterine growth retardation (IUGR), polyhydramnios, congenital heart defects, genitourinary anomalies, micrognathia, and omphalocele [4]. However, abnormalities of the central nervous system may not always be detected by fetal ultrasound or MRI, particularly at early gestational ages. Recently, molecular genetic methods, such as chromosome microarray analysis (CMA) and BACs-on-Beads assay, have become useful for prenatally diagnosing MDS and 17p13.3 duplication syndrome [4,5,6,7,8,9,10]. In clinical samples, these microdeletions or microduplications involving 17p13.3 detected by CMA often differ in size and gene content. Therefore, their clinical significance requires careful interpretation. In this study, we retrospectively analyzed eight patients with copy number variants (CNVs) involving 17p13.3 by single nucleotide polymorphism (SNP) analysis over 4.5 years. We provide clinical and molecular data of patients with causal chromosomal aberrations and/or variants of uncertain significance and discuss the potential implications of phenotype-associated genes located within these CNVs.

Materials and methods


Eight patients with CNVs involving 17p13.3 were identified out of 8,806 samples subjected to SNP array analysis at the Fujian Provincial Maternity and Child Health Hospital from January 2016 to June 2020. These eight cases included five fetuses with various invasive diagnostic indications (cases 1–5), one aborted embryo (case 6), and two children with congenital malformations (cases 7 and 8). The clinical findings and genetic analyses of these cases included fetal ultrasound, karyotyping, SNP analysis, parental testing when possible, pregnancy outcomes, and clinical manifestations.

SNP array analysis

Genomic DNA was obtained from the amniotic fluid, umbilical cord blood, villus, or peripheral blood and isolated using a QIAamp DNA Blood Mini kit (QIAGEN, Germany). Furthermore, CNVs were detected using the genome-wide CytoScan 750 K SNP array following the manufacturer’s instructions (Thermo Fisher Scientific Inc, Singapore). The raw data were analyzed using the Chromosome Analysis Suite (ChAS) software, version 3.1 (Thermo Fisher Scientific Inc, Singapore), and genomic imbalances were annotated based on GRCh37/hg19 Genome Build (July 2013). All CNVs were analyzed at a resolution of 100 kb/50 markers. The laboratory reported microdeletions or microduplications > 400 kb. For patients with abnormal microarray results, parental testing was performed, where possible, to determine the inheritance pattern of the deletion and/or duplication using CMA and/or standard karyotyping.

To classify the CNVs, their type (duplication or deletion), size, location, gene content, and inheritance pattern (when DNA samples of a patient′s parents were available), as well as the patient’s phenotype and clinical data were considered. We searched several genome variant databases, including the Database of Genomic Variants (, Online Mendelian Inheritance in Man (, ClinVar (, ClinGen Dosage Sensitivity Curations ( =), DECIPHER (, and published literature ( CNVs were finally classified as (1) pathogenic, (2) likely pathogenic, (3) variants of uncertain significance, (4) likely benign, or (5) benign, following the guidelines of American College of Medical Genetics and Genomics [11].


Karyotyping was performed for all prenatal cases. The samples were cultured and prepared for Giemsa banding according to standard cytogenetic protocols, and the International System for Human Cytogenetic Nomenclature (2016) was used for karyotyping and description.

Pregnancy outcome and follow-up

Pregnancy outcomes were abstracted from the delivery records of patients in our hospital. Otherwise, follow-ups were conducted with patients before and after delivery via telephone. During follow-ups, physical (length, weight, and head circumference) and mental (major movements, minor movements, cognitive ability, and intelligence) developments of the newborns were examined.


Clinical findings of patients

The prenatal findings varied significantly among the five fetuses. Case 1 showed a slightly fast heart rate (165 beats per minute) on prenatal ultrasound at 18 weeks of gestation, and the mother presented with intellectual disability. In the first trimester, case 2 had an isolated increased nuchal translucency (NT) (3.7 mm). Subsequently, the increased NT resolved, and no other abnormalities were found later in pregnancy. Case 3 was found to have a ventricular septal defect and dysplasia of the corpus callosum at 26+ weeks of gestation. In case 4, non-invasive prenatal testing indicated two segmental deletions on the short arm of chromosome 17, which necessitated an invasive prenatal diagnosis of the fetus. Case 5 exhibited multiple abnormalities, including IUGR, shallow cerebral cortex, small thymus, low conus spinalis, overlapping fingers, and polyhydramnios at 28 weeks of gestation. Case 6 was a spontaneously aborted embryo, and two children (cases 7 and 8) manifested severe congenital defects. Detailed clinical information is listed in Table 1.

Table 1 Eight cases found with copy number variants involving 17p13.3 by SNP array


Five fetuses underwent chromosomal karyotyping. Apart from case 3, no obvious abnormality was found in the other fetuses. As shown in Fig. 1, the karyotype of case 3 was 46,XY,r(17)(p13q25).

Fig. 1
figure 1

The karyotype of case 3 was 46,XY,r(17)(p13q25). The arrow points to a ring chromosome 17

SNP results

CNVs involving 17p13.3 were detected in eight out of the 8,808 subjects, including two duplications and six deletions (Fig. 2; Additional file 1: Figure S1). The detected CNVs involving 17p13.3 ranged in size from 576 kb to 5.7 Mb; except for the microduplication in case 2, these CNVs were identified as pathogenic (Table 1). The fetus (case 2) harbored a 576 kb duplication within the 17p13.3 band, encompassing YWHAE and CRK but not PAFAH1B1, inherited from the mother who was healthy without apparently dysmorphism and has received an undergraduate education.

Fig. 2
figure 2

Eight cases with copy number variants (CNVs) involving 17p13.3 in our study. a The ideogram of chromosome 17 shows the region of interest as well as the three main genes (YWHAE, CRK, and PAFAH1B1). The orange bar represents the Miller–Dieker syndrome (MDS) critical region. b Sizes and locations of CNVs found in our patients. Red and blue bars represent copy number deletions and duplications, respectively. #: Case 3 also carried a 74.2 Mb mosaic duplication of approximately 3.5 on chromosome 17p13.2q25.3 and a 1.0 Mb deletion at 17q25.3. Case 8 also had a 4.0 Mb duplication at 17q25.3

In addition, two cases (cases 3 and 8) carried other CNVs apart from 17p13.3 microdeletions. Notably, case 3 also carried a 74.2 Mb mosaic duplication of approximately 3.5 on chromosome 17p13.2q25.3 and a 1.0 Mb deletion in 17q25.3. This occurrence was indicative of the “ring chromosome 17” anomaly that was confirmed by karyotyping (Fig. 1). Case 8 also had a 4.0 Mb duplication at the 17q terminus; this duplication and deletion, occurring on the same chromosome, were most likely owing to a parental pericentric inversion.

Pregnancy outcome

Of the five prenatal cases, only case 2 continued gestation, whereas the other fetuses were subjected to termination of pregnancy. Currently, this baby is 15 months old and has no obvious dysmorphic features. The height (80 cm) and weight (10.5 kg) are within the normal range. Motor function (major and fine movements) and mental development are normal as examined by physicians in community hospitals.


Genomic imbalances in 17p13.3 are mainly associated with neuronal migration disorders. A ~ 1.3 Mb deletion within the 17p13.3 region extending from YWHAE to PAFAH1B1 is sufficient to cause MDS. In addition, recent studies have focused on a condition known as 17p13.3 microduplication syndrome [2, 3, 12]. Since individuals with either condition often exhibit poor prognosis, prenatal diagnosis of these genomic disorders is crucial. To investigate the clinical significance of CNVs involving 17p13.3 with varied sizes and gene content, we retrospectively analyzed the clinical data of eight cases. In addition, we discussed the potential implications of phenotype-associated genes located within these CNVs.

The CNVs involving 17p13.3 contained or overlapped with the MDS region in the eight cases. SNP array provided genetic diagnosis of MDS for cases 4, 6, and 7 and 17p13.3 duplication syndrome for case 1. Of these, case 7 displayed developmental delay (DD), congenital lissencephaly, and softening of the brain. In case 6, MDS may be the underlying cause of spontaneous abortion. In contrast, case 4 had no obvious clinical findings associated with MDS on the first-trimester ultrasound. MDS features, such as polyhydramnios, IUGR, ventriculomegaly, lissencephaly, and corpus callosum dysgenesis/agenesis, were often found in the second and third trimesters [4]. Apart from this, case 1 had no abnormalities in brain structure and no IUGR, both of which were previously described in the 17p13.3 duplication syndrome [10].

Apart from the cases with definite syndromes mentioned above, we focused on the clinical significance of CNVs involving 17p13.3 that overlapped with the MDS region. Currently, MDS is regarded as a contiguous gene deletion syndrome, and PAFAH1B1, YWHAE, and CRK in this region are of prime interest. PAFAH1B1 is considered to cause an isolated lissencephaly sequence and contribute to MDS [3, 13]. YWHAE encodes 14-3-3ε, a phosphoserine/threonine-binding protein that plays a role in cortical development [14, 15]. In addition, YWHAE and TUSC5 appear to contribute to craniofacial dysmorphism [3], while CRK functions in cell proliferation, differentiation, migration, and axonal growth and is a typical candidate gene for growth restriction. Moreover, CRK appears to be related to limb abnormalities and craniofacial dysmorphism [2, 16, 17].

Case 5 harbored a de novo 2.1 Mb deletion containing YWHAE and CRK but not PAFAH1B1 and showed multiple abnormalities in the prenatal ultrasound. As previously reported, neurodevelopmental delay, growth retardation, craniofacial dysmorphisms, mild structural brain abnormalities, and seizures were observed in 17p13.3 deletions, including YWHAE and CRK but not PAFAH1B1 [14, 18, 19]. Similarly, case 8 carried a 1.6 Mb deletion in the 17p13.3 region encompassing YWHAE and CRK, along with a 4.0 Mb duplication in the 17q25.3 region. Previous studies have reported that 17q25.3 duplication was related to DD, growth retardation, and multiple congenital anomalies [20, 21]. Therefore, we hypothesized that deletions and duplications may contribute to the clinical phenotype of this patient. Overall, the 17p13.3 microdeletion including YWHAE and CRK but not PAFAH1B1 could be classified as pathogenic.

In case 2, the 17p13.3 duplication that included YWHAE and CRK was inherited from unaffected mother, and the ultrasound revealed a transient increase in NT. The fetus was then continued developing and had a good presentation at 15 months old. The duplication in case 2 can be identified as class I of 17p13.3 microduplication syndrome [3]. The individuals in this category, including three patients from Bruno et al. [3] (cases 9, 11 and 12) and four from Bi et al. [22] (subjects 1–4), had autism manifestations, behavioral symptoms, learning disabilities, subtle dysmorphic facial features, subtle hand/foot malformations, and a tendency to postnatal overgrowth, among other disorders. Another study from Curry et al. [23] described eight patients in Group 1 17p13.3 microduplications who presented with developmental, behavioral and brain abnormalities, and rare variant phenotypes such as cleft palate and split hand/foot with long bone deficiency. Regarding inheritance of these 15 patients, six were de novo, six were inherited from an unaffected parent, and three were unknown. The duplication inherited from a normal parent may be owing to reduced penetrance and variable expressivity. In addition, we searched the DECIPHER database and found 12 duplications involving YWHAE and CRK, but not PAFAH1B1, which was approximately 300 kb. Eight out of 12 cases lacked parental analysis and showed a wide spectrum of phenotypes not characterized by autism. Therefore, the extent of contribution of the variants to their phenotypes cannot be ascertained.

Furthermore, the likelihood of a single-gene mutation causing propositus manifestations cannot be ruled out. The two-hit model proposed by Girirajan et al. [24] suggests that a secondary disruptive event (another CNV, a point mutation or environment factors) could result in more severe clinical manifestations in neurodevelopmental diseases. Likewise, Tolezano et al. [25] investigated the genetic factors that contribute to variable expressivity of class I 17p13.3 microduplications, providing new evidence regarding the contribution of RORA and DIP2B to neurocognitive deficits such as autism and intellectual disability, respectively. Moreover, in group I 17p13.3 microduplication, Curry et al. [23] reported that disruption of ABR and duplication of BHLHA9 were associated with clefts and split hand/foot with long bone deficiency phenotypes, respectively. Capra et al. [26] reported that a boy carrying a maternally inherited 329.5-kb 17p13.3 duplication, including BHLHA9, YWHAE, and CRK, presented with mild dysmorphic phenotype, autism, and mental retardation, while his mother was affected by a bipolar and borderline disorder and was addicted to alcohol. It can be seen that phenotypic heterogeneity existed in the mother and her child. Another report [27] described two patients manifesting distinctive features (patient 1, primary hypothyroidism; patient 2, bilateral cryptorchidism) that were not previously described in the duplication 17p13.3 spectrum. Whether these rare manifestations observed in the two patients were caused by a two-hit event or not is not known. Overall, considering 17p13.3 microduplication showing reduced penetrance, variable expressivity, and lack of a clear pathogenic mechanism, the clinical significance of the microduplication encompassing only YWHAE and CRK, but not PAFAH1B1, requires further investigation.

Interestingly, case 3 also carried a 74.2 Mb mosaic duplication of approximately 3.5 on chromosome 17p13.2q25.3 and a 1.0 Mb deletion in the 17q terminus, in addition to deletion of the MDS region. The SNP data were consistent with that some cells have ring 17 while others have dicentric or interlock ring 17. Given the dosage sensitivity of genes and regions involved in the three CNVs, case 3 may show compound manifestations of these known genomic disorders, such as MDS, Potocki–Lupski syndrome (MIM:610883) [12], Charcot–Marie–Tooth disease, type 1A (CMT1A, MIM:118220) [28, 29], 17q11.2 duplication syndrome, 1.4-Mb (618874) [30, 31] and 17q12 duplication syndrome (MIM:614526) [32, 33]. Notably, the karyotype of case 3 is similar to previously reported “ring chromosome 17” syndrome [34], the manifestations of which include DD, seizures, short statures, microcephaly, and muscular hypotonia, among others. In contrast, ventricular septal defect and dysplasia of the corpus callosum were observed on ultrasound at 26+ weeks of gestation while other features could not be detected in the prenatal ultrasound.

A total of eight cases were detected with CNVs involving 17p13.3 in our report. However, the size and number of genes involved differed considerably, particularly when mixed deletion and duplication at chromosome 17 terminations and ring chromosome 17 were observed. It is estimated that approximately 80% of MDS cases are de novo, and approximately 20% of the conditions arise from balanced chromosomal rearrangement in parents 4. To our knowledge, no data have been presented from large-scale case studies to calculate the frequencies of 17p13.3 microduplication, mixed deletion/duplication on chromosome 17, and ring chromosome 17 to date, indicating the need for further study.

Our study has some limitations. First, its single-center nature and small number of patients resulted in fewer detectable 17p13.3 CNVs. Second, owing to the lack of functional experiments, whether the genes inside the duplication in case 2 are overexpressed is uncertain. Third, despite its notable advantages in CNV detection, SNP array cannot detect point mutations associated with neurodevelopmental disorders. Recently, with the development of next-generation sequencing, whole-exome or whole-genome sequencing may provide clinically relevant information in cases where SNP array fails to determine the underlying cause of a neurodevelopmental disorder.


The clinical findings of 17p13.3 microdeletions or microduplications varied among subjects. SNP array allowed for accurate identification of CNV syndromes. Nevertheless, identifying the clinical significance of a CNV that overlaps with the MDS region in prenatal diagnosis remains challenging. While the microdeletions that include YWHAE and CRK are likely pathogenic, the clinical significance of small duplications encompassing YWHAE and CRK but not PAFAH1B1 remains uncertain, rendering prenatal genetic counseling difficult. Therefore, further molecular and clinical delineation of 17p13.3 microdeletions or duplications is needed to enrich published literature and databases. Combining SNP array and next-generation sequencing might provide a good option for genetic analysis in patients with the abnormalities of central nervous system.

Availability of data and materials

All data generated or analyzed during this study are included in this article. The original data that support the findings of this study are available from the corresponding author upon reasonable request.



Copy number variants


Single nucleotide polymorphism


Miller–Dieker syndrome


Magnetic resonance imaging


Intrauterine growth retardation


Chromosome microarray analysis


Nuchal translucency


Developmental delay


  1. Cardoso C, Leventer RJ, Ward HL, et al. Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3. Am J Hum Genet. 2003;72(4):918–30.

    Article  CAS  Google Scholar 

  2. Blazejewski SM, Bennison SA, Smith TH, Toyo-Oka K. Neurodevelopmental genetic diseases associated with microdeletions and microduplications of chromosome 17p13.3. Front Genet. 2018;9:80.

    Article  Google Scholar 

  3. Bruno DL, Anderlid BM, Lindstrand A, et al. Further molecular and clinical delineation of co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes. J Med Genet. 2010;47(5):299–311.

    Article  CAS  Google Scholar 

  4. Chen CP, Chang TY, Guo WY, et al. Chromosome 17p13.3 deletion syndrome: aCGH characterization, prenatal findings and diagnosis, and literature review. Gene. 2013;532(1):152–9.

    Article  CAS  Google Scholar 

  5. Shi X, Huang W, Lu J, He W, Liu Q, Wu J. Prenatal diagnosis of Miller–Dieker syndrome by chromosomal microarray. Ann Hum Genet. 2021;85(2):92–6.

    Article  CAS  Google Scholar 

  6. Zhang H, Yang X, Tang X, Li G, Tang D, Huang Z. Prenatal diagnosis of a fetus with Miller–Dieker syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020;37(11):1280–2.

    Google Scholar 

  7. Duan F, Kong X. Prenatal diagnosis and genetic analysis of a fetus with Miller–Dieker syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2021;38(1):71–3.

    Google Scholar 

  8. Lin S, Luo Y, Wu J, Chen B, Ji Y, Zhou Y. Prenatal genetic analysis of two fetuses with Miller–Dieker syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2017;34(1):89–92.

    Google Scholar 

  9. Xu L, Huang H, Wang Y, et al. Prenatal diagnosis of a fetus with Miller–Dieker syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2017;34(6):879–83.

    Google Scholar 

  10. Kiiski K, Roovere T, Zordania R, von Koskull H, Horelli-Kuitunen N. Prenatal diagnosis of 17p13.1p13.3 duplication. Case Rep Med. 2012;2012:840538.

    Article  Google Scholar 

  11. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020;22(2):245–57.

    Article  Google Scholar 

  12. Shchelochkov OA, Cheung SW, Lupski JR. Genomic and clinical characteristics of microduplications in chromosome 17. Am J Med Genet A. 2010;152A(5):1101–10.

    Article  CAS  Google Scholar 

  13. Dobyns WB, Reiner O, Carrozzo R, Ledbetter DH. Lissencephaly: a human brain malformation associated with deletion of the LIS1 gene located at chromosome 17p13. JAMA. 1993;270(23):2838–42.

    Article  CAS  Google Scholar 

  14. Enomoto K, Kishitani Y, Tominaga M, et al. Expression analysis of a 17p terminal deletion, including YWHAE, but not PAFAH1B1, associated with normal brain structure on MRI in a young girl. Am J Med Genet A. 2012;158(9):2347–52.

    Article  CAS  Google Scholar 

  15. Mignon-Ravix C, Cacciagli P, El-Waly B, et al. Deletion of YWHAE in a patient with periventricular heterotopias and pronounced corpus callosum hypoplasia. J Med Genet. 2010;47(2):132–6.

    Article  CAS  Google Scholar 

  16. Ostergaard JR, Graakjaer J, Brandt C, Birkebaek NH. Further delineation of 17p133 microdeletion involving CRK: the effect of growth hormone treatment. Eur J Med Genet. 2012;55(1):22–6.

    Article  Google Scholar 

  17. Barros Fontes MI, Dos Santos AP, Rossi Torres F, et al. 17p13.3 microdeletion: insights on genotype-phenotype correlation. Mol Syndromol. 2017;8(1):36–41.

    Article  CAS  Google Scholar 

  18. Romano C, Ferranti S, Mencarelli MA, Longo I, Renieri A, Grosso S. 17p13.3 microdeletion including YWHAE and CRK genes: towards a clinical characterization. Neurol Sci. 2020;41(8):2259–62.

    Article  Google Scholar 

  19. Tenney JR, Hopkin RJ, Schapiro MB. Deletion of 14-3-3{varepsilon} and CRK: a clinical syndrome with macrocephaly, developmental delay, and generalized epilepsy. J Child Neurol. 2011;26(2):223–7.

    Article  Google Scholar 

  20. Wang Q, Li Q, Xu Q, Liu Y, Yuan H. Identification of a 17q253 duplication in a Chinese patient with global developmental delay and multiple congenital anomalies. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020;37(1):52–6.

    CAS  Google Scholar 

  21. Lukusa T, Fryns JP. Pure de novo 17q25.3 micro duplication characterized by micro array CGH in a dysmorphic infant with growth retardation, developmental delay and distal arthrogryposis. Genet Couns. 2010;21(1):25–34.

    CAS  Google Scholar 

  22. Bi W, Sapir T, Shchelochkov OA, et al. Increased LIS1 expression affects human and mouse brain development. Nat Genet. 2009;41(2):168–77.

    Article  CAS  Google Scholar 

  23. Curry CJ, Rosenfeld JA, Grant E, et al. The duplication 17p13.3 phenotype: analysis of 21 families delineates developmental, behavioral and brain abnormalities, and rare variant phenotypes. Am J Med Genet A. 2013;161(8):1833–52.

    Article  CAS  Google Scholar 

  24. Girirajan S, Rosenfeld JA, Cooper GM, et al. A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet. 2010;42(3):203–9.

    Article  CAS  Google Scholar 

  25. Tolezano GC, da Costa SS, Scliar MO, et al. Investigating genetic factors contributing to variable expressivity of class I 17p13.3 microduplication. Int J Mol Cell Med. 2020;9(4):296–306.

    CAS  Google Scholar 

  26. Capra V, Mirabelli-Badenier M, Stagnaro M, et al. Identification of a rare 17p13.3 duplication including the BHLHA9 and YWHAE genes in a family with developmental delay and behavioural problems. BMC Med Genet. 2012;13:93.

    Article  CAS  Google Scholar 

  27. Farra C, Abdouni L, Hani A, et al. 17p13.3 Microduplication syndrome: further delineating the clinical spectrum. J Pediatr Genet. 2021;10(3):239–44.

    Article  Google Scholar 

  28. Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p112 in Charcot–Marie–Tooth neuropathy type 1a (CMT 1a): The HMSN Collaborative Research Group. Neuromuscul Disord. 1991;1(2):93–7.

    Article  CAS  Google Scholar 

  29. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot–Marie–Tooth disease type 1A. Cell. 1991;66(2):219–32.

    Article  CAS  Google Scholar 

  30. Moles KJ, Gowans GC, Gedela S, et al. NF1 microduplications: identification of seven nonrelated individuals provides further characterization of the phenotype. Genet Med. 2012;14(5):508–14.

    Article  CAS  Google Scholar 

  31. Grisart B, Rack K, Vidrequin S, et al. NF1 microduplication first clinical report: association with mild mental retardation, early onset of baldness and dental enamel hypoplasia? Eur J Hum Genet. 2008;16(3):305–11.

    Article  CAS  Google Scholar 

  32. Nagamani SC, Erez A, Shen J, et al. Clinical spectrum associated with recurrent genomic rearrangements in chromosome 17q12. Eur J Hum Genet. 2010;18(3):278–84.

    Article  CAS  Google Scholar 

  33. Bierhals T, Maddukuri SB, Kutsche K, et al. Expanding the phenotype associated with 17q12 duplication: case report and review of the literature. Am J Med Genet A. 2013;161A(2):352–9.

    Article  Google Scholar 

  34. Carpenter NJ, Leichtman LG, Stamper S, Say B. An infant with ring 17 chromosome and unusual dermatoglyphs: a new syndrome? J Med Genet. 1981;18(3):234–6.

    Article  CAS  Google Scholar 

Download references


We are grateful to the patients and their families for their collaboration.


This work was supported by grants from Fujian Provincial Health Technology Project (Grant No. 2020GGB018, 2020CXB008); Joints Funds for the Innovation of Science and Technology, Fujian Province (Grant No. 2020Y9159, 2021Y9179).

Author information

Authors and Affiliations



BL, DY, and LX contributed to the conception and design of the study. WZ, YW, XW, LC and NL collected clinical data and performed genetic analysis. BL and DY wrote the first draft of the manuscript. HH and LX revised the manuscript. All authors read and approved the submitted version.

Corresponding authors

Correspondence to Na Lin, Hailong Huang or Liangpu Xu.

Ethics declarations

Ethics approval and consent to participate

All experiments were performed in accordance with relevant guidelines and regulations. The present study was approved by the Protection of Human Ethics Committee of Fujian Provincial Maternity and Children’s Hospital (No. 2020KY113). Written informed consent was obtained from individual or guardian participants.

Consent for publication

All participants provided informed consent and they agreed to publish their clinical data.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

 Single nucleotide polymorphism array results of eight cases with 17p13.3 copy number variants identified in our study.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liang, B., Yu, D., Zhao, W. et al. Clinical findings and genetic analysis of patients with copy number variants involving 17p13.3 using a single nucleotide polymorphism array: a single-center experience. BMC Med Genomics 15, 268 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Miller–Dieker syndrome
  • 17p13.3 Duplication syndrome
  • CNV involving 17p13.3
  • Single nucleotide polymorphism array
  • Genetic analysis